November 19th, 2007 
Deepak Ranbaxy Laboratories Ranbaxy Laboratories Limited, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. It is headquartered in India. The Company is ranked amongst the top ten global generic companies and has a presence in 23 of the top 25 pharma markets of the world. The Company with a global footprint in 49 countries, world-class manufacturing facilities in 11 and a diverse product portfolio, is rapidly moving towards global leadership, riding on its success in the world’s emerging and developed markets. Wire money online to India with Xoom.com for as low as $4.99. Ranbaxy Laboratories Limited was incorporated in 1961. The CEO of the company is Malvinder Mohan Singh. The company was made public in 1973. Ranbaxy is one of the leading pharma Companies in India commanding a market share of 5.07%. In 1998, Ranbaxy entered the United States of America, the world’s largest pharmaceuticals market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy’s sales. The Company’s business has been realigned to its customer groups and investments have been made in high growth segments. These efforts have resulted in strengthening its Chronic franchise (Life Style led) as well as has reinforced its leading position in the acute segment. Most of Ranbaxy’s products are manufactured by license from foreign pharmaceutical developers, though a significant percentage of their products are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired. The Company has successfully pursued its inorganic growth strategy and concluded over 15 acquisitions since 2004, including the latest 9 acquisitions valued at US$ 450 Mn (4 in Europe, 1 in the US, 3 in India and 1 in South Africa). These acquisitions have significantly expanded its business in emerging and profitable markets. The Company will continue to evaluate acquisition options in US, Europe, India and emerging markets to accentuate its business and competitiveness in these markets. Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide the company with a sustainable, long-term competitive advantage. The Company today has a pool of 1,200 scientists who are engaged in path-breaking research. Ranbaxy is among the few Indian pharmaceutical companies in India to have initiated its research program in the late 70’s. To support its global ambition [...]
Posted in 
